Evidence map›Paper›PMID 40900285›Full record

ArticleAnnals of nuclear medicine2025

Establishment of National Diagnostic Reference Levels 2025 for nuclear medicine in Japan.

Koichiro Abe, Shingo Baba, Reo Etani, Takahiro Fujimto, Makoto Hosono, Takashi Iimori, Anri Inaki, Masanobu Ishiguro, Noriaki Miyaji, Atsutaka Okizaki and 5 more

Abstract read
In one paragraph

Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Koichiro Abe *Department of Radiology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-Ku, Tokyo, 160-0023, Japan. k-abe@tokyo-med.ac.jp.ORCID http://orcid.org/0000-0003-0549-9122
Shingo Baba *Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Reo Etani *Department of Environmental Health Science, Oita University of Nursing and Health Sciences, 2944-9 Megusuno, Oita, 870-1201, Japan.
Takahiro Fujimto *Division of Clinical Radiology Service, Kyoto University Hospital, 54 Shogoin-Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan.
Makoto Hosono *Department of Radiology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka, Osaka-Sayama, 589-8511, Japan.
Takashi Iimori *Department of Radiology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Anri Inaki *Division of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Masanobu Ishiguro *Section of Radiology, Fujita Health University Hospital, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Noriaki Miyaji *Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University, 10-6 Sakaemachi, Fukushima, 960-8516, Japan.
Atsutaka Okizaki *Department of Radiology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido, 078-8510, Japan.
Takeshi Sasaki *Department of Radiologic Technology, Ageo Central General Hospital, 1-10-10 Kashiwaza, Ageo, Saitama, 362-8588, Japan.
Hiroyuki Tsushima *Department of Radiological Technology, Kobe Tokiwa University, 2-6-2 Otanicho, Nagata-Ku, Kobe, Hyogo, 653-0838, Japan.
Hiroshi Watanabe *Department of Radiological Sciences, Gunma Paz University, 1-7-1 Tonya-Machi, Takasaki, Gunma, 370-0006, Japan.
Masanori Watanabe *Section of Radiology, Fujita Health University Hospital, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Nobuhiro Yada *Department of Radiology, Shimane University Hospital, 89-1 Enya-Cho, Izumo, Shimane, 693-8501, Japan.

Funding

Health Labour Sciences Research Grant 25IA1007
6 · The paper itself

Abstract

Diagnostic reference levels (DRLs) are practical benchmarks for optimizing patient radiation exposure in medical imaging. In Japan, national DRLs, including those for nuclear medicine together and other radiological procedures, were first established in 2015 and revised in 2020. In this study, we revised the DRL values of nuclear medicine for the establishment of DRLs2025, based on data collected from institutions nationwide throughout Japan. Data were collected via an online survey from facilities performing nuclear medicine procedures, including SPECT, PET, and hybrid CT imaging. Information on dose activity of the administered radiopharmaceuticals and CT parameters (CTDIvol and DLP) were collected. DRL values were determined through analysis of the submitted data, supplemented by panel discussions among experts taking into account the clinical appropriateness of the values and various technological factors. Overall, the newly established DRLs2025 demonstrated a decreasing trend in administered radiopharmaceutical activities, CTDIvol, and DLP compared with the previous surveys. This trend reflects ongoing efforts toward the optimization of radiation exposure and radiopharmaceutical dose reduction, likely driven by the introduction of image reconstruction methods based on newer technologies. However, substantial interfacility variations were observed, particularly in the CT parameters, suggesting disparities in equipment, imaging protocols, and the balance between image quality and radiation dose. The establishment of DRLs2025 underscores continued progress in optimizing radiation exposure in nuclear medicine practice in Japan. Although issues regarding data variability and quality remain, DRLs continue to be a key tool in radiation protection and quality assurance. Ongoing efforts to improve data collection systems and to align procedures with international standards are essential for the future refinement of DRLs.

Indexed as

Nuclear MedicineDiagnostic Reference LevelsHumansJapanRadiation DosageRadiopharmaceuticalsRadiopharmaceuticalsDiagnostic reference levelHybrid CTNational DRLNuclear medicineRadiopharmaceutical

Identifiers

PMID40900285
PMCPMC12450211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.